As of November this year, based on Johnson & Johnson's most recent financial report, the company's trailing twelve months EPS is $10.43. Johnson & Johnson's earnings per share in 2024 was reported at $5.84, marking a decline from $13.88 in 2023. Johnson & Johnson's EPS for the quarterly period ending on Sep 28, 2025 came in at $2.14.
The yearly earnings per share during 2024 was $5.84, a decline of 57.9% compared to $13.88 recorded in 2023. The quarterly earnings per share for the period ending Sep 28, 2025, was $2.14, showing a 91.1% increase compared to the same quarter last year. The trailing twelve months EPS for JNJ is $10.43 as of September 2025. Johnson & Johnson's full-year EPS for 2023 was $13.88, a 103.2% rise compared to the previous year.
In the past 12 months, Johnson & Johnson has recorded an earnings per share growth rate of 91.1% (YoY, quarterly). Across the past three years, the company had an average EPS annual growth rate of -9.7% per year. In the last five years, the company had an average annual EPS growth of 0.4%. When assessed over a ten-year period, JNJ's average EPS annual growth was 0.1%.
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| MRK Merck & Co Inc | 12.98 | 4,728.6% | 9.4% | 12% |
| PFE Pfizer Inc | 14.31 | 273.7% | -28.7% | -13.2% |
| ABT Abbott Laboratories | 15.57 | 133.8% | 24.5% | 29.9% |
| NVS Novartis AG | 17.03 | -17.2% | -17.9% | 2.9% |
| JNJ Johnson & Johnson | 17.83 | -57.9% | -9.7% | 0.4% |
| GILD Gilead Sciences Inc | 24.27 | -91.6% | -57.5% | -38.3% |
| MDT Medtronic plc | 24.84 | 31% | -1.1% | 0.3% |
| LLY ELI LILLY & Co | 45.18 | 102.1% | 24.1% | 5.7% |
| SYK Stryker Corp | 46.33 | -5.8% | 14.1% | 7.1% |
All data is based on quarterly TTM periods, unless otherwise specified.